Skip to content
Open access

Real-World Treatment Outcomes and Prognostic Factors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer: A Single-Center Study from a High-Volume Tertiary Chest Hospital

Oct 2026 · Journal of Clinical Medicine · Vol 15 · 0 citations · 36 references
Medicine

TL;DR

The survival outcomes observed in this cohort were generally consistent with previously published real-world data in EGFR-mutant metastatic NSCLC, and ECOG performance status and bone metastasis were significantly associated with OS, while associations involving histopathological subtype and uncommon EGFR mutations should be considered exploratory.

Abstract

Background/Objectives: Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is a distinct molecular subgroup responsive to EGFR tyrosine kinase inhibitors (TKIs). This study evaluated real-world treatment outcomes and prognostic factors in patients with EGFR-mutated metastatic NSCLC. Methods: This retrospective study included 124 patients treated with first-line EGFR-TKIs between January 2017 and 30 August 2025 at a tertiary center. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and prognostic factors were assessed using Cox proportional hazards models. Results: The median age was 66 years, and 63.7% of patients were female. The most common mutation was exon 19 deletion (65.3%). Median OS for the entire cohort was 31.7 months, and median PFS was 16.3 months. In multivariate analysis, Eastern Cooperative Oncology Group performance status (ECOG PS), histopathological subtype, uncommon EGFR mutations, and bone metastasis were statistically significantly associated with OS in multivariable Cox regression analysis. Among patients receiving second-line treatment, median PFS was 16.7 months with osimertinib and 4.1 months with platinum-based chemotherapy; these nonrandomized treatment-specific outcomes were considered descriptive. Conclusions: In conclusion, the survival outcomes observed in our cohort were generally consistent with previously published real-world data in EGFR-mutant metastatic NSCLC. ECOG performance status and bone metastasis were significantly associated with OS, while associations involving histopathological subtype and uncommon EGFR mutations should be considered exploratory given the small subgroup sizes and limited statistical power. These findings provide real-world evidence on treatment patterns and survival outcomes among patients with EGFR-mutant metastatic NSCLC in Türkiye.

Read PDF

Similar papers

Open access Oct 2026

Real-world outcomes of caucasians with EGFR -mutated non-small-cell lung cancer treated with surgery (EXERPOS-2 GFPC study)

Little is known about the natural history of epidermal growth factor receptor ( EGFR) -mutated non-small-cell lung cancer (NSCLC) in Caucasian patients treated with surgery before the generalization of adjuvant treatment with osimertinib. The primary objective of this study was to describe the outcomes...

J. Auliac, P. Thomas, O. Bylicki et al. · 0 citations
Open access Oct 2026

Overall survival prediction and risk stratification for advanced EGFR-mutant lung adenocarcinoma patients treated with first-line tyrosine kinase inhibitors

Lung adenocarcinoma (LAD) is the most common non-small cell lung cancer subtype, with frequent epidermal growth factor receptor (EGFR) mutations in Asians. First-line tyrosine kinase inhibitors (TKIs) improves survival but resistance is inevitable, leading to disease progression and even death. We aimed to develo...

Wen-Jian Tang, Jia-Wei Feng, Yuan Kang et al. · 0 citations
Open access Aug 2026

Clinical Outcomes and Prognostic Factors in Driver-Negative Stage IV Non-small Cell Lung Cancer Patients Receiving Thoracic Radiotherapy: A Single-Center Retrospective Study.

IntroductionThe role of thoracic radiotherapy (TRT) in stage IV non-small cell lung cancer (NSCLC) without targetable driver alterations remains unclear. We evaluated outcomes, prognostic factors, and safety in patients receiving TRT and systemic therapy.MethodsIn this single-center retrospective cohort study, we analy...

Chao-Zhen Shang, Jiang-Ping Yang, Miao Wang et al. · 0 citations
Open access Sep 2026

Real-world outcomes of neoadjuvant targeted therapy in resectable epidermal growth factor receptor mutation-positive non-small cell lung cancer: a retrospective study

Background Multiple clinical trials have validated the efficacy of neoadjuvant targeted therapy (NTT) for resectable non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. This retrospective study aimed to assess the efficacy and safety of neoadjuvant EGFR-tyrosine kinase inhibi...

Jian-Bang Li, Yin-Guang Zhang, Jie Gao et al. · 0 citations
Open access Sep 2026

Genomic characteristics, survival, and prognostic analysis of advanced non-small cell lung cancer with KRAS mutations and brain metastases

Background The brain is a common site of metastasis in lung cancer. However, data on the incidence of brain metastases (BM) and survival outcomes among patients with non-small cell lung cancer (NSCLC) harboring KRAS mutations, particularly those receiving tyrosine kinase inhibitors (TKIs), remain limited. This single-c...

Yi Chen, Xi-He Yu, Meng-Qi Bao et al. · 0 citations
Open access Oct 2026

Rare epidermal growth factor receptor (EGFR) mutations in completely resected stage I lung adenocarcinoma: a real-world study of mutation spectrum, clinicopathological features, and prognosis

Background Rare epidermal growth factor receptor (EGFR) mutations are heterogeneous, and their significance after complete resection of stage I lung adenocarcinoma (LUAD) remains unclear. We evaluated the mutation spectrum, clinicopathological correlates, postoperative recurrence patterns, and survival outcomes of a st...

La-Jie Man, Liang Xia, Chuan Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.